Market Cap (In USD)
4.73 Million
Revenue (In USD)
-
Net Income (In USD)
-1.33 Million
Avg. Volume
5169.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.013-0.077
- PE
- -
- EPS
- -
- Beta Value
- 1.074
- ISIN
- US1231591058
- CUSIP
- 123159105
- CIK
- 724445
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Stanislaw R. Burzynski M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.burzynskiclinic.com
- Ipo Date
- 1997-01-02
- Details
- Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
More Stocks
-
ZEEL
-
NEWD
-
UMBF
-
BEM-R
-
BSM
-
002900
-
HAGHensoldt AG
HAG
-
STI